[1]
|
MAHMOOD H,FAHEEM M,MAHMOOD S,et al.Impact of age,tumor size,lymph node metastasis,stage,receptor status and menopausal status on overall survival of breast cancer patients in Pakistan[J].Asian Pae J Cancer Prev,2015,16(3):1019. |
[2]
|
FOULKES WD,SMITH IE,REIS-FILHO JS.Triple-negative breast cancer[J].N Engl J Med,2010,363:1938. |
[3]
|
HAN W,KIM SW.Young age:an independent risk factor for disease-free survival in women with operable breast cancer[J].BMC Cancer,2004(4):82. |
[4]
|
邵志敏,沈镇宙.乳腺癌的预后因素研究进展[J].中国癌症杂志,2001,11(5):96. |
[5]
|
CARTER CL,ALLEN C,HENSON DE.Relation of tumor size,lymph node status,and survival in 24 740 breast cancer cases[J].Cancer,1989,63(1):181. |
[6]
|
沈松杰,孙强,周易冬,等.三阴性乳腺癌预后相关因素分析[J].中华外科杂志,2013,51(11):1000. |
[7]
|
YAO-LUNG K,CHEN DR,CHANG TW.Clinicopathological features of triple-negative breast cancer in Taiwanese women[J].Int J Clin Oncol,2011,16(5):500. |
[8]
|
TURKER I,ARSLAN UY,YAZICI O,et al.Prognostic Factors in Operated Stage ⅢC,Pathological N3a Breast Cancer Patients[J].Breast Care,2014,9(6):421. |
[9]
|
曹华,闫茂生,郑涛,等.132例三阴性乳腺癌患者的临床特征与预后分析[J].实用肿瘤学杂志,2009,23(2):101. |
[10]
|
Early Breast Cancer Trialists' Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomized trials[J].Lancet,2005,365(9472):1687. |
[11]
|
倪晨,李婷,吴振华,等.三阴性乳腺癌化疗进展[J].中国癌症杂志,2014,24(4):316. |
[12]
|
JONES RL,WALSH G,ASHLEY S,et al.A randomised pilot Phase Ⅱ study of doxorubicin and cyclophosphamide(AC)or epirubicin and cyclophosphamide(EC) given 2 weekly with pegfilgrastim(accelerated) vs 3 weekly(standard) for women with early breast cancer[J].Br J Cancer,2009,100(2):305. |
[13]
|
RANGAN AM,AHERN V,YIP D,et al.Local recurrence after mastectomy and adjuvant CMF:implications for adjuvant radiation therapy[J].Aust N Z Surg,2000,70(9):649. |
[14]
|
HUANG CJ,HOU MF,CHUANG HY,et al.Comparison of clinical outcome of breast cancer patients with T1-2 tumor and one to three positive nodes with or without postmastectomy radiation therapy[J].Jpn J Clin Oncol,2012,42(8):711. |
[15]
|
DURAKER N,DEMIR D,BATI B,et al.Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis[J].Jpn J Clin Oncol,2012,42(7):601. |
[16]
|
COSAR R,UZAL C,TOKATLI F,et al.Postmastectomy irradiation in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes:is there a role for radiation therapy?[J].Radiat Oncol,2011,6(1):28. |
[17]
|
SU Y,ZHENG Y,ZHENG W,et al.Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinesewomen:a population-based cohort study[J].BMC Cancer,2011,11(1):292. |
[18]
|
YIN W,JIANG Y,SHEN Z,et al.Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients:a meta-analysis of published randomized controlled trials[J].PLoS One,2011,6(6):e21030. |